July 31, 2012
The device can be integrated with drugs and pharmaceuticals.
The company has been awarded the ISO 13485 certification for electroporation devices.
The device treats benign prostatic hyperplasia.
NSF's list of services will be complemented by what Becker & Associates brings to the table.
The money will fund an expansion of the university’s Medical Devices Center.
ImageIQ will provide imaging analytics to Histogenics.
Fresenius insists it still has buying power for a takeover of Rhoen-Klinikum.
The company highlights the cost effectiveness of its new products.
The Frost & Sullivan Award recognizes innovation among other achievements.
CEO says company will be able to match human tissue closer than ever before.
The companies hope to get medical devices to market sooner by joining forces.
The company is questioned for a possible delay in public disclosure.
STERIS CEO dubs the deal the company’s “most significant” in a long time.
The deal is anticipated to close by the third quarter of 2012.
Senator puts pressure on FDA to explain itself.
New owner pledges growth.
The conference will focus on local companies and connect industry players.
BD will gain a line of anti-needlestick devices.
The new R&D center will focus on the cardiovascular and neuromodulation markets.
Winning Apps will present at Medica 2012.
The amendments have supporters and dissidents from all sides.
Internal funding will go toward an annuplasty device, while external funds fuel spin-off.
News of the deal has caused dismay among investors.
The respiratory device company will introduce a new product to the Brazilian market.
The bill’s approval has been praised for its rare bipartisan effort.
The company attracts Medtronic executive to fill the role.
The stent joins the company’s Evolution line of stents.
The neurological device is already approved to treat a number of other disorders.
Device identification is mandated by the recently passed user fee legislation.
The system will be used in prostatectomies.
The device is under review for the CE Mark.
Please visit our sister sites:
The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.